Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Ann Burtness, Kevin Joseph Harrington, Richard Greil et al. · The Lancet · 2019

Cited by 3,304 works. doi:10.1016/s0140-6736(19)32591-7 Open-access PDF

Authors

References